ARTICLE | Politics, Policy & Law
Piloting a new course to reimbursing antibiotics
Two European pilots and U.S. legislation aim to revamp the commercial market for antibiotics
April 10, 2020 3:06 PM UTC
Updated on Apr 10, 2020 at 9:26 PM UTC
The shockingly fast speed at which COVID-19 turned from a regional breakout to a global pandemic with no treatments has made it easy to imagine a similar epidemic arising from multi-drug resistant bacteria, adding new urgency to the need to fix the dysfunctional market for antibiotics.
Antibiotic development is stuck in a negative feedback loop -- with no viable commercial market for new therapies, R&D investment has nearly disappeared...